Chief Market Strategist
Ross Givens is a veteran trader with over 15 years of experience and a former VP at a major Wall Street investment bank. Specializing in small-cap stocks and momentum-driven plays, Ross identifies high-probability setups before they hit the mainstream. As Lead Strategist at Traders Agency, he has guided hundreds of successful trades and developed multiple flagship publications.
The SpaceX IPO is going LIVE today. What’s going to happen next – and does the massive hype mark the “top” for the market? Find out inside.
AI picks and shovels stocks are the smartest trade in the boom. Atkore, Belden, and Methode supply every data center at a fraction of the crowd's 40x valua
The SpaceX IPO is going LIVE today. What’s going to happen next – and does the massive hype mark the “top” for the market? Find out inside.
A Pentagon defense contract small cap could hand a $6 stock a $200M loitering munition award. Which company holds exclusive Israeli combat drone rights?
Smart money stock picks are beating the SpaceX IPO pop. These 4 backdoor plays in AI infrastructure and oil shipping offer real upside without chasing hype
SpaceX is now trading -- here's when to buy SpaceX shares for the lowest price. Lockup expirations create a mid-August window smart traders won't miss.
The SpaceX IPO is going LIVE today. What’s going to happen next – and does the massive hype mark the “top” for the market? Find out inside.
The government erasing national debt through inflation is already underway. Here's how debt monetization works and which mining stocks stand to benefit mos
The SpaceX IPO is going LIVE today. What’s going to happen next – and does the massive hype mark the “top” for the market? Find out inside.
Agentic AI stocks are entering a new phase as 1.4B knowledge workers replace chatbots with autonomous agents. These 3 backdoor infrastructure plays could e
The pullback continues. But the question on people’s minds is – could the SpaceX IPO end the pullback? Ross investigates.
FDA drug rejection reversal almost never happens — but it did for Outlook Therapeutics. OTLK trades under $1 with an FDA decision due in roughly 60 days.
50,000+ traders get our daily brief before the market opens.
You're subscribed!
Check your inbox.
Free. No spam. Unsubscribe anytime.